{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:20:20Z","timestamp":1790828420013,"version":"4.1.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2021,6,6]],"date-time":"2021-06-06T00:00:00Z","timestamp":1622937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,6]],"date-time":"2021-06-06T00:00:00Z","timestamp":1622937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["MAESTRO grant 2018\/30\/A\/NZ3\/00412"],"award-info":[{"award-number":["MAESTRO grant 2018\/30\/A\/NZ3\/00412"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Dystrophin is a large protein serving as local scaffolding repetitively bridging cytoskeleton and the outside of striated muscle cell. As such dystrophin is a critical brick primarily in dystrophin-associated protein complex (DAGC) and in a larger submembranous unit, costamere. Accordingly, the lack of functional dystrophin laying at the root of Duchenne muscular dystrophy (DMD) drives sarcolemma instability. From this point on, the cascade inevitably leading to the death of myocyte begins. In cardiomyocytes, intracellular calcium overload and related mitochondrial-mediated cell death mainly contribute to myocardial dysfunction and dilation while other protein dysregulation and\/or mislocalization may affect electrical conduction system and favor arrhythmogenesis. Although clinically DMD manifests as progressive muscle weakness and skeletal muscle symptoms define characteristic of DMD, it is the heart problem the biggest challenge that most often develop in the form of dilated cardiomyopathy (DCM). Current standards of treatment and recent progress in respiratory care, introduced in most settings in the 1990s, have improved quality of life and median life expectancy to 4th decade of patient\u2019s age. At the same time, cardiac causes of death related to DMD increases. Despite preventive and palliative cardiac treatments available, the prognoses remain poor. Direct therapeutic targeting of dystrophin deficiency is critical, however, hindered by the large size of the dystrophin cDNA and\/or stochastic, often extensive genetic changes in\n                    <jats:italic>DMD<\/jats:italic>\n                    gene. The correlation between cardiac involvement and mutations affecting specific dystrophin isoforms, may provide a mutation-specific cardiac management and novel therapeutic approaches for patients with CM. Nonetheless, the successful cardiac treatment poses a big challenge and may require combined therapy to combat dystrophin deficiency and its after-effects (critical in DMD pathogenesis). This review locates the multifaceted heart problem in the course of DMD, balancing the insights into basic science, translational efforts and clinical manifestation of dystrophic heart disease.\n                  <\/jats:p>","DOI":"10.1007\/s00018-021-03862-2","type":"journal-article","created":{"date-parts":[[2021,6,6]],"date-time":"2021-06-06T08:04:17Z","timestamp":1622966657000},"page":"5447-5468","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["The multifaceted view of heart problem in Duchenne muscular dystrophy"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4500-0405","authenticated-orcid":false,"given":"Urszula","family":"Florczyk-Soluch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4204-9745","authenticated-orcid":false,"given":"Katarzyna","family":"Polak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5687-0839","authenticated-orcid":false,"given":"J\u00f3zef","family":"Dulak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,6]]},"reference":[{"key":"3862_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","volume":"15","author":"S Crisafulli","year":"2020","unstructured":"Crisafulli S, Sultana J, Fontana A et al (2020) Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis 15:141. https:\/\/doi.org\/10.1186\/s13023-020-01430-8","journal-title":"Orphanet J Rare Dis"},{"key":"3862_CR2","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/cphy.c140048","volume":"5","author":"Q Gao","year":"2015","unstructured":"Gao Q, McNally EM (2015) The dystrophin complex: structure, function and implications for therapy. Compr Physiol 5:1223\u20131239. https:\/\/doi.org\/10.1002\/cphy.c140048","journal-title":"Compr Physiol"},{"key":"3862_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7090291","author":"D D\u2019Amario","year":"2018","unstructured":"D\u2019Amario D, Gowran A, Canonico F et al (2018) Dystrophin cardiomyopathies: clinical management, molecular pathogenesis and evolution towards precision medicine. J Clin Med. https:\/\/doi.org\/10.3390\/jcm7090291","journal-title":"J Clin Med"},{"key":"3862_CR4","doi-asserted-by":"publisher","first-page":"13591","DOI":"10.1074\/jbc.R200021200","volume":"278","author":"JM Ervasti","year":"2003","unstructured":"Ervasti JM (2003) Costameres: the Achilles\u2019 heel of Herculean muscle. J Biol Chem 278:13591\u201313594. https:\/\/doi.org\/10.1074\/jbc.R200021200","journal-title":"J Biol Chem"},{"key":"3862_CR5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10654-020-00613-8","volume":"35","author":"E Landfeldt","year":"2020","unstructured":"Landfeldt E, Thompson R, Sejersen T et al (2020) Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. Eur J Epidemiol 35:643\u2013653. https:\/\/doi.org\/10.1007\/s10654-020-00613-8","journal-title":"Eur J Epidemiol"},{"key":"3862_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.nmd.2010.09.006","volume":"21","author":"Y Ishikawa","year":"2011","unstructured":"Ishikawa Y, Miura T, Ishikawa Y et al (2011) Duchenne muscular dystrophy: survival by cardio-respiratory interventions. Neuromuscul Disord 21:47\u201351. https:\/\/doi.org\/10.1016\/j.nmd.2010.09.006","journal-title":"Neuromuscul Disord"},{"key":"3862_CR7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.rehab.2013.06.002","volume":"56","author":"P Kieny","year":"2013","unstructured":"Kieny P, Chollet S, Delalande P et al (2013) Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011. Ann Phys Rehabil Med 56:443\u2013454. https:\/\/doi.org\/10.1016\/j.rehab.2013.06.002","journal-title":"Ann Phys Rehabil Med"},{"key":"3862_CR8","first-page":"121","volume":"31","author":"L Passamano","year":"2012","unstructured":"Passamano L, Taglia A, Palladino A et al (2012) Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients. Acta Myol 31:121\u2013125","journal-title":"Acta Myol"},{"key":"3862_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11897-020-00456-0","volume":"17","author":"JA Shih","year":"2020","unstructured":"Shih JA, Folch A, Wong BL (2020) Duchenne muscular dystrophy: the heart of the matter. Curr Heart Fail Rep 17:57\u201366. https:\/\/doi.org\/10.1007\/s11897-020-00456-0","journal-title":"Curr Heart Fail Rep"},{"key":"3862_CR10","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s00246-020-02309-y","volume":"41","author":"CA Wittlieb-Weber","year":"2020","unstructured":"Wittlieb-Weber CA, Knecht KR, Villa CR et al (2020) Risk factors for cardiac and non-cardiac causes of death in males with duchenne muscular dystrophy. Pediatr Cardiol 41:764\u2013771. https:\/\/doi.org\/10.1007\/s00246-020-02309-y","journal-title":"Pediatr Cardiol"},{"key":"3862_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0167-5273(90)90082-g","volume":"26","author":"G Nigro","year":"1990","unstructured":"Nigro G, Comi LI, Politano L, Bain RJ (1990) The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 26:271\u2013277. https:\/\/doi.org\/10.1016\/0167-5273(90)90082-g","journal-title":"Int J Cardiol"},{"key":"3862_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12981-5","author":"N Doorenweerd","year":"2017","unstructured":"Doorenweerd N, Mahfouz A, van Putten M et al (2017) Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-017-12981-5","journal-title":"Sci Rep"},{"key":"3862_CR13","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1021\/acsomega.9b02911","volume":"5","author":"V Upadhyay","year":"2020","unstructured":"Upadhyay V, Bandi S, Panja S et al (2020) Tissue-specificity of dystrophin-actin interactions: isoform-specific thermodynamic stability and actin-binding function of tandem calponin-homology domains. ACS Omega 5:2159\u20132168. https:\/\/doi.org\/10.1021\/acsomega.9b02911","journal-title":"ACS Omega"},{"key":"3862_CR14","doi-asserted-by":"publisher","first-page":"S929","DOI":"10.1007\/s100720070006","volume":"21","author":"NH Keep","year":"2000","unstructured":"Keep NH (2000) Structural comparison of actin binding in utrophin and dystrophin. Neurol Sci 21:S929-937. https:\/\/doi.org\/10.1007\/s100720070006","journal-title":"Neurol Sci"},{"key":"3862_CR15","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1073\/pnas.1211431109","volume":"110","author":"Y Lai","year":"2013","unstructured":"Lai Y, Zhao J, Yue Y, Duan D (2013) \u03b12 and \u03b13 helices of dystrophin R16 and R17 frame a microdomain in the \u03b11 helix of dystrophin R17 for neuronal NOS binding. Proc Natl Acad Sci USA 110:525\u2013530. https:\/\/doi.org\/10.1073\/pnas.1211431109","journal-title":"Proc Natl Acad Sci USA"},{"key":"3862_CR16","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00018-019-03006-7","volume":"76","author":"P Podkalicka","year":"2019","unstructured":"Podkalicka P, Mucha O, Dulak J, Loboda A (2019) Targeting angiogenesis in Duchenne muscular dystrophy. Cell Mol Life Sci 76:1507\u20131528. https:\/\/doi.org\/10.1007\/s00018-019-03006-7","journal-title":"Cell Mol Life Sci"},{"key":"3862_CR17","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.nmd.2015.09.011","volume":"25","author":"JP Gonzalez","year":"2015","unstructured":"Gonzalez JP, Crassous P-A, Schneider JS et al (2015) Neuronal nitric oxide synthase localizes to utrophin expressing intercalated discs and stabilizes their structural integrity. Neuromuscul Disord 25:964\u2013976. https:\/\/doi.org\/10.1016\/j.nmd.2015.09.011","journal-title":"Neuromuscul Disord"},{"key":"3862_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1042\/BJ20120787","volume":"449","author":"J Ramachandran","year":"2013","unstructured":"Ramachandran J, Schneider JS, Crassous P-A et al (2013) Nitric oxide signaling pathway in duchenne muscular dystrophy mice: upregulation of L-arginine transporters. Biochem J 449:133\u2013142. https:\/\/doi.org\/10.1042\/BJ20120787","journal-title":"Biochem J"},{"key":"3862_CR19","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1073\/pnas.96.2.657","volume":"96","author":"KY Xu","year":"1999","unstructured":"Xu KY, Huso DL, Dawson TM et al (1999) Nitric oxide synthase in cardiac sarcoplasmic reticulum. Proc Natl Acad Sci USA 96:657\u2013662. https:\/\/doi.org\/10.1073\/pnas.96.2.657","journal-title":"Proc Natl Acad Sci USA"},{"key":"3862_CR20","doi-asserted-by":"publisher","first-page":"14126","DOI":"10.1073\/pnas.241380298","volume":"98","author":"AJ Kanai","year":"2001","unstructured":"Kanai AJ, Pearce LL, Clemens PR et al (2001) Identification of a neuronal nitric oxide synthase in isolated cardiac mitochondria using electrochemical detection. Proc Natl Acad Sci USA 98:14126\u201314131. https:\/\/doi.org\/10.1073\/pnas.241380298","journal-title":"Proc Natl Acad Sci USA"},{"key":"3862_CR21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3390\/brainsci5030275","volume":"5","author":"B Nichols","year":"2015","unstructured":"Nichols B, Takeda S, Yokota T (2015) Nonmechanical roles of dystrophin and associated proteins in exercise, neuromuscular junctions, and brains. Brain Sci 5:275\u2013298. https:\/\/doi.org\/10.3390\/brainsci5030275","journal-title":"Brain Sci"},{"key":"3862_CR22","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/s0960-8966(99)00048-6","volume":"9","author":"S Torelli","year":"1999","unstructured":"Torelli S, Ferlini A, Obici L et al (1999) Expression, regulation and localisation of dystrophin isoforms in human foetal skeletal and cardiac muscle. Neuromuscul Disord 9:541\u2013551. https:\/\/doi.org\/10.1016\/s0960-8966(99)00048-6","journal-title":"Neuromuscul Disord"},{"key":"3862_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/ajmg.1320560207","volume":"56","author":"F Muntoni","year":"1995","unstructured":"Muntoni F, Melis MA, Ganau A, Dubowitz V (1995) Transcription of the dystrophin gene in normal tissues and in skeletal muscle of a family with X-linked dilated cardiomyopathy. Am J Hum Genet 56:151\u2013157","journal-title":"Am J Hum Genet"},{"key":"3862_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-2350-13-20","volume":"13","author":"M Neri","year":"2012","unstructured":"Neri M, Valli E, Alfano G et al (2012) The absence of dystrophin brain isoform expression in healthy human heart ventricles explains the pathogenesis of 5\u2019 X-linked dilated cardiomyopathy. BMC Med Genet 13:20. https:\/\/doi.org\/10.1186\/1471-2350-13-20","journal-title":"BMC Med Genet"},{"key":"3862_CR25","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/BF02265272","volume":"97","author":"E Holder","year":"1996","unstructured":"Holder E, Maeda M, Bies RD (1996) Expression and regulation of the dystrophin Purkinje promoter in human skeletal muscle, heart, and brain. Hum Genet 97:232\u2013239. https:\/\/doi.org\/10.1007\/BF02265272","journal-title":"Hum Genet"},{"key":"3862_CR26","doi-asserted-by":"publisher","first-page":"e001782","DOI":"10.1161\/CIRCGEN.117.001782","volume":"11","author":"T Yamamoto","year":"2018","unstructured":"Yamamoto T, Awano H, Zhang Z et al (2018) cardiac dysfunction in duchenne muscular dystrophy is less frequent in patients with mutations in the dystrophin Dp116 coding region than in other regions. Circ Genom Precis Med 11:e001782. https:\/\/doi.org\/10.1161\/CIRCGEN.117.001782","journal-title":"Circ Genom Precis Med"},{"key":"3862_CR27","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1172\/JCI118112","volume":"96","author":"F Muntoni","year":"1995","unstructured":"Muntoni F, Wilson L, Marrosu G et al (1995) A mutation in the dystrophin gene selectively affecting dystrophin expression in the heart. J Clin Invest 96:693\u2013699","journal-title":"J Clin Invest"},{"key":"3862_CR28","doi-asserted-by":"publisher","first-page":"9996","DOI":"10.1074\/jbc.M513121200","volume":"281","author":"IN Rybakova","year":"2006","unstructured":"Rybakova IN, Humston JL, Sonnemann KJ, Ervasti JM (2006) Dystrophin and utrophin bind actin through distinct modes of contact. J Biol Chem 281:9996\u201310001. https:\/\/doi.org\/10.1074\/jbc.M513121200","journal-title":"J Biol Chem"},{"key":"3862_CR29","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1021\/acs.biochem.6b01117","volume":"56","author":"SM Singh","year":"2017","unstructured":"Singh SM, Bandi S, Mallela KMG (2017) The N-terminal flanking region modulates the actin binding affinity of the utrophin tandem calponin-homology domain. Biochemistry 56:2627\u20132636. https:\/\/doi.org\/10.1021\/acs.biochem.6b01117","journal-title":"Biochemistry"},{"key":"3862_CR30","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1093\/hmg\/ddz049","volume":"28","author":"S Guiraud","year":"2019","unstructured":"Guiraud S, Edwards B, Babbs A et al (2019) The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy. Hum Mol Genet 28:2189\u20132200. https:\/\/doi.org\/10.1093\/hmg\/ddz049","journal-title":"Hum Mol Genet"},{"key":"3862_CR31","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1083\/jcb.201212142","volume":"201","author":"F Rahimov","year":"2013","unstructured":"Rahimov F, Kunkel LM (2013) The cell biology of disease: cellular and molecular mechanisms underlying muscular dystrophy. J Cell Biol 201:499\u2013510. https:\/\/doi.org\/10.1083\/jcb.201212142","journal-title":"J Cell Biol"},{"key":"3862_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9020520","author":"ML Law","year":"2020","unstructured":"Law ML, Cohen H, Martin AA et al (2020) Dysregulation of calcium handling in duchenne muscular dystrophy-associated dilated cardiomyopathy: mechanisms and experimental therapeutic strategies. J Clin Med. https:\/\/doi.org\/10.3390\/jcm9020520","journal-title":"J Clin Med"},{"key":"3862_CR33","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.bbamem.2013.07.011","volume":"1838","author":"V Sequeira","year":"2014","unstructured":"Sequeira V, Nijenkamp LLAM, Regan JA, van der Velden J (2014) The physiological role of cardiac cytoskeleton and its alterations in heart failure. Biochim Biophys Acta 1838:700\u2013722. https:\/\/doi.org\/10.1016\/j.bbamem.2013.07.011","journal-title":"Biochim Biophys Acta"},{"key":"3862_CR34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ppedcard.2011.02.003","volume":"31","author":"AK Peter","year":"2011","unstructured":"Peter AK, Cheng H, Ross RS et al (2011) The costamere bridges sarcomeres to the sarcolemma in striated muscle. Prog Pediatr Cardiol 31:83\u201388. https:\/\/doi.org\/10.1016\/j.ppedcard.2011.02.003","journal-title":"Prog Pediatr Cardiol"},{"key":"3862_CR35","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/s1474-4422(03)00585-4","volume":"2","author":"F Muntoni","year":"2003","unstructured":"Muntoni F, Torelli S, Ferlini A (2003) Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2:731\u2013740. https:\/\/doi.org\/10.1016\/s1474-4422(03)00585-4","journal-title":"Lancet Neurol"},{"key":"3862_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135189","volume":"10","author":"J Juan-Mateu","year":"2015","unstructured":"Juan-Mateu J, Gonzalez-Quereda L, Rodriguez MJ et al (2015) DMD mutations in 576 dystrophinopathy families: a step forward in genotype-phenotype correlations. PLOS ONE 10:e0135189. https:\/\/doi.org\/10.1371\/journal.pone.0135189","journal-title":"PLOS ONE"},{"key":"3862_CR37","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","volume":"2","author":"AP Monaco","year":"1988","unstructured":"Monaco AP, Bertelson CJ, Liechti-Gallati S et al (1988) An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2:90\u201395. https:\/\/doi.org\/10.1016\/0888-7543(88)90113-9","journal-title":"Genomics"},{"issue":"Pt 22","key":"3862_CR38","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1242\/jcs.110.22.2873","volume":"110","author":"BL Hodges","year":"1997","unstructured":"Hodges BL, Hayashi YK, Nonaka I et al (1997) Altered expression of the alpha7beta1 integrin in human and murine muscular dystrophies. J Cell Sci 110(Pt 22):2873\u20132881","journal-title":"J Cell Sci"},{"key":"3862_CR39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41536-018-0045-4","volume":"3","author":"N Yucel","year":"2018","unstructured":"Yucel N, Chang AC, Day JW et al (2018) Humanizing the mdx mouse model of DMD: the long and the short of it. NPJ Regen Med 3:4. https:\/\/doi.org\/10.1038\/s41536-018-0045-4","journal-title":"NPJ Regen Med"},{"key":"3862_CR40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0960-8966(92)90004-p","volume":"2","author":"TR Helliwell","year":"1992","unstructured":"Helliwell TR, Man NT, Morris GE, Davies KE (1992) The dystrophin-related protein, utrophin, is expressed on the sarcolemma of regenerating human skeletal muscle fibres in dystrophies and inflammatory myopathies. Neuromuscul Disord 2:177\u2013184. https:\/\/doi.org\/10.1016\/0960-8966(92)90004-p","journal-title":"Neuromuscul Disord"},{"key":"3862_CR41","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/s0092-8674(00)80533-4","volume":"90","author":"RM Grady","year":"1997","unstructured":"Grady RM, Teng H, Nichol MC et al (1997) Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 90:729\u2013738. https:\/\/doi.org\/10.1016\/s0092-8674(00)80533-4","journal-title":"Cell"},{"key":"3862_CR42","doi-asserted-by":"publisher","first-page":"e28569","DOI":"10.1371\/journal.pone.0028569","volume":"7","author":"DJ Stuckey","year":"2012","unstructured":"Stuckey DJ, Carr CA, Camelliti P et al (2012) In vivo MRI characterization of progressive cardiac dysfunction in the mdx mouse model of muscular dystrophy. PLoS ONE 7:e28569. https:\/\/doi.org\/10.1371\/journal.pone.0028569","journal-title":"PLoS ONE"},{"key":"3862_CR43","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1093\/hmg\/ddl083","volume":"15","author":"KA Kleopa","year":"2006","unstructured":"Kleopa KA, Drousiotou A, Mavrikiou E et al (2006) Naturally occurring utrophin correlates with disease severity in Duchenne muscular dystrophy. Hum Mol Genet 15:1623\u20131628. https:\/\/doi.org\/10.1093\/hmg\/ddl083","journal-title":"Hum Mol Genet"},{"key":"3862_CR44","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/BF00314217","volume":"236","author":"D Cros","year":"1989","unstructured":"Cros D, Harnden P, Pellissier JF, Serratrice G (1989) Muscle hypertrophy in Duchenne muscular dystrophy. A pathological and morphometric study. J Neurol 236:43\u201347. https:\/\/doi.org\/10.1007\/BF00314217","journal-title":"J Neurol"},{"key":"3862_CR45","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00256-011-1240-1","volume":"41","author":"M Torriani","year":"2012","unstructured":"Torriani M, Townsend E, Thomas BJ et al (2012) Lower leg muscle involvement in Duchenne muscular dystrophy: an MR imaging and spectroscopy study. Skeletal Radiol 41:437\u2013445. https:\/\/doi.org\/10.1007\/s00256-011-1240-1","journal-title":"Skeletal Radiol"},{"key":"3862_CR46","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1007\/s12035-019-01845-w","volume":"57","author":"M Naidoo","year":"2020","unstructured":"Naidoo M, Anthony K (2020) Dystrophin Dp71 and the neuropathophysiology of duchenne muscular dystrophy. Mol Neurobiol 57:1748\u20131767. https:\/\/doi.org\/10.1007\/s12035-019-01845-w","journal-title":"Mol Neurobiol"},{"key":"3862_CR47","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/emmm.201100133","volume":"3","author":"D Cacchiarelli","year":"2011","unstructured":"Cacchiarelli D, Legnini I, Martone J et al (2011) miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Mol Med 3:258\u2013265. https:\/\/doi.org\/10.1002\/emmm.201100133","journal-title":"EMBO Mol Med"},{"key":"3862_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/DNND.S121099","volume":"8","author":"CA-K Szigyarto","year":"2018","unstructured":"Szigyarto CA-K, Spitali P (2018) Biomarkers of Duchenne muscular dystrophy: current findings. Degener Neurol Neuromuscul Dis 8:1\u201313. https:\/\/doi.org\/10.2147\/DNND.S121099","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"3862_CR49","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1631\/jzus.B1800541","volume":"20","author":"Y Yang","year":"2019","unstructured":"Yang Y, Yan K, Liu B et al (2019) Comprehensive genetic diagnosis of patients with Duchenne\/Becker muscular dystrophy (DMD\/BMD) and pathogenicity analysis of splice site variants in the DMD gene. J Zhejiang Univ Sci B 20:753\u2013765. https:\/\/doi.org\/10.1631\/jzus.B1800541","journal-title":"J Zhejiang Univ Sci B"},{"key":"3862_CR50","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.braindev.2018.06.012","volume":"40","author":"E Takeshita","year":"2018","unstructured":"Takeshita E, Komaki H, Tachimori H et al (2018) Urinary prostaglandin metabolites as Duchenne muscular dystrophy progression markers. Brain Dev 40:918\u2013925. https:\/\/doi.org\/10.1016\/j.braindev.2018.06.012","journal-title":"Brain Dev"},{"key":"3862_CR51","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/BF01243426","volume":"46","author":"Y Dalmaz","year":"1979","unstructured":"Dalmaz Y, Peyrin L, Mamelle JC et al (1979) The pattern of urinary catecholamines and their metabolites in Duchenne myopathy, in relation to disease evolution. J Neural Transm 46:17\u201334. https:\/\/doi.org\/10.1007\/BF01243426","journal-title":"J Neural Transm"},{"key":"3862_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20174098","author":"TA Meyers","year":"2019","unstructured":"Meyers TA, Townsend D (2019) Cardiac Pathophysiology and the Future of Cardiac Therapies in Duchenne Muscular Dystrophy. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20174098","journal-title":"Int J Mol Sci"},{"key":"3862_CR53","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1161\/CIRCRESAHA.117.311812","volume":"121","author":"B Eugene","year":"2017","unstructured":"Eugene B (2017) Cardiomyopathies. Circ Res 121:711\u2013721. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311812","journal-title":"Circ Res"},{"key":"3862_CR54","unstructured":"Mahmaljy H, Yelamanchili VS, Singhal M (2020) Dilated cardiomyopathy. In: StatPearls. StatPearls Publishing, Treasure Island (FL)"},{"key":"3862_CR55","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1161\/01.cir.93.5.841","volume":"93","author":"P Richardson","year":"1996","unstructured":"Richardson P, McKenna W, Bristow M et al (1996) Report of the 1995 World Health Organization\/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93:841\u2013842. https:\/\/doi.org\/10.1161\/01.cir.93.5.841","journal-title":"Circulation"},{"key":"3862_CR56","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41572-019-0084-1","volume":"5","author":"H-P Schultheiss","year":"2019","unstructured":"Schultheiss H-P, Fairweather D, Caforio ALP et al (2019) Dilated cardiomyopathy. Nat Rev Dis Primers 5:32. https:\/\/doi.org\/10.1038\/s41572-019-0084-1","journal-title":"Nat Rev Dis Primers"},{"key":"3862_CR57","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","volume":"342","author":"GM Felker","year":"2000","unstructured":"Felker GM, Thompson RE, Hare JM et al (2000) Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342:1077\u20131084. https:\/\/doi.org\/10.1056\/NEJM200004133421502","journal-title":"N Engl J Med"},{"key":"3862_CR58","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s12471-012-0285-7","volume":"20","author":"M Hazebroek","year":"2012","unstructured":"Hazebroek M, Dennert R, Heymans S (2012) Idiopathic dilated cardiomyopathy: possible triggers and treatment strategies. Neth Heart J 20:332\u2013335. https:\/\/doi.org\/10.1007\/s12471-012-0285-7","journal-title":"Neth Heart J"},{"key":"3862_CR59","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","volume":"121","author":"AJ Marian","year":"2017","unstructured":"Marian AJ, Braunwald E (2017) Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 121:749\u2013770. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311059","journal-title":"Circ Res"},{"key":"3862_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd4010003","author":"D Masarone","year":"2017","unstructured":"Masarone D, Limongelli G, Rubino M et al (2017) Management of arrhythmias in heart failure. J Cardiovasc Dev Dis. https:\/\/doi.org\/10.3390\/jcdd4010003","journal-title":"J Cardiovasc Dev Dis"},{"key":"3862_CR61","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jacc.2008.12.032","volume":"53","author":"KN Hor","year":"2009","unstructured":"Hor KN, Wansapura J, Markham LW et al (2009) Circumferential strain analysis identifies strata of cardiomyopathy in Duchenne muscular dystrophy: a cardiac magnetic resonance tagging study. J Am Coll Cardiol 53:1204\u20131210. https:\/\/doi.org\/10.1016\/j.jacc.2008.12.032","journal-title":"J Am Coll Cardiol"},{"key":"3862_CR62","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.echo.2016.07.001","volume":"29","author":"JH Soslow","year":"2016","unstructured":"Soslow JH, Xu M, Slaughter JC et al (2016) Evaluation of echocardiographic measures of left ventricular function in patients with duchenne muscular dystrophy: assessment of reproducibility and comparison to cardiac magnetic resonance imaging. J Am Soc Echocardiogr 29:983\u2013991. https:\/\/doi.org\/10.1016\/j.echo.2016.07.001","journal-title":"J Am Soc Echocardiogr"},{"key":"3862_CR63","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/CND.0000000000000204","volume":"20","author":"S Poonja","year":"2018","unstructured":"Poonja S, Power A, Mah JK et al (2018) Current cardiac imaging approaches in duchenne muscular dystrophy. J Clin Neuromuscul Dis 20:85\u201393. https:\/\/doi.org\/10.1097\/CND.0000000000000204","journal-title":"J Clin Neuromuscul Dis"},{"key":"3862_CR64","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001338","author":"A Tandon","year":"2015","unstructured":"Tandon A, Villa CR, Hor KN et al (2015) Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in duchenne muscular dystrophy. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.114.001338","journal-title":"J Am Heart Assoc"},{"key":"3862_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/genes8040108","author":"VPA Johnstone","year":"2017","unstructured":"Johnstone VPA, Viola HM, Hool LC (2017) Dystrophic cardiomyopathy-potential role of calcium in pathogenesis treatment and novel therapies. Genes (Basel). https:\/\/doi.org\/10.3390\/genes8040108","journal-title":"Genes (Basel)"},{"key":"3862_CR66","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3389\/fphys.2016.00429","volume":"7","author":"MA de Marques","year":"2016","unstructured":"de Marques MA, de Oliveira GAP (2016) Cardiac troponin and tropomyosin: structural and cellular perspectives to unveil the hypertrophic cardiomyopathy phenotype. Front Physiol 7:429. https:\/\/doi.org\/10.3389\/fphys.2016.00429","journal-title":"Front Physiol"},{"key":"3862_CR67","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1126\/science.1202768","volume":"333","author":"BL Prosser","year":"2011","unstructured":"Prosser BL, Ward CW, Lederer WJ (2011) X-ROS signaling: rapid mechano-chemo transduction in heart. Science 333:1440\u20131445. https:\/\/doi.org\/10.1126\/science.1202768","journal-title":"Science"},{"key":"3862_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1357-2725(99)00095-3","volume":"32","author":"JG Tidball","year":"2000","unstructured":"Tidball JG, Spencer MJ (2000) Calpains and muscular dystrophies. Int J Biochem Cell Biol 32:1\u20135. https:\/\/doi.org\/10.1016\/S1357-2725(99)00095-3","journal-title":"Int J Biochem Cell Biol"},{"key":"3862_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1113\/jphysiol.2002.017129","volume":"541","author":"BJ Wilkins","year":"2002","unstructured":"Wilkins BJ, Molkentin JD (2002) Calcineurin and cardiac hypertrophy: where have we been? Where are we going? J Physiol (Lond) 541:1\u20138. https:\/\/doi.org\/10.1113\/jphysiol.2002.017129","journal-title":"J Physiol (Lond)"},{"key":"3862_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8122151","author":"G Esposito","year":"2019","unstructured":"Esposito G, Carsana A (2019) Metabolic alterations in cardiomyocytes of patients with duchenne and becker muscular dystrophies. J Clin Med. https:\/\/doi.org\/10.3390\/jcm8122151","journal-title":"J Clin Med"},{"key":"3862_CR71","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00246-015-1331-1","volume":"37","author":"JA Su","year":"2016","unstructured":"Su JA, Ramos-Platt L, Menteer J (2016) Left ventricular tonic contraction as a novel biomarker of cardiomyopathy in duchenne muscular dystrophy. Pediatr Cardiol 37:678\u2013685. https:\/\/doi.org\/10.1007\/s00246-015-1331-1","journal-title":"Pediatr Cardiol"},{"key":"3862_CR72","doi-asserted-by":"publisher","first-page":"13490","DOI":"10.1038\/srep13490","volume":"5","author":"JP Gonzalez","year":"2015","unstructured":"Gonzalez JP, Ramachandran J, Xie L-H et al (2015) Selective Connexin43 Inhibition Prevents Isoproterenol-Induced Arrhythmias and Lethality in Muscular Dystrophy Mice. Sci Rep 5:13490. https:\/\/doi.org\/10.1038\/srep13490","journal-title":"Sci Rep"},{"key":"3862_CR73","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1093\/hmg\/ddi197","volume":"14","author":"M Wehling-Henricks","year":"2005","unstructured":"Wehling-Henricks M, Jordan MC, Roos KP et al (2005) Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium. Hum Mol Genet 14:1921\u20131933. https:\/\/doi.org\/10.1093\/hmg\/ddi197","journal-title":"Hum Mol Genet"},{"key":"3862_CR74","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","volume":"391","author":"CM McDonald","year":"2018","unstructured":"McDonald CM, Henricson EK, Abresch RT et al (2018) Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet 391:451\u2013461. https:\/\/doi.org\/10.1016\/S0140-6736(17)32160-8","journal-title":"Lancet"},{"key":"3862_CR75","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.jpeds.2013.05.060","volume":"163","author":"BJ Barber","year":"2013","unstructured":"Barber BJ, Andrews JG, Lu Z et al (2013) Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy. J Pediatr 163:1080-1084.e1. https:\/\/doi.org\/10.1016\/j.jpeds.2013.05.060","journal-title":"J Pediatr"},{"key":"3862_CR76","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.pediatrneurol.2007.11.001","volume":"38","author":"S Houde","year":"2008","unstructured":"Houde S, Filiatrault M, Fournier A et al (2008) Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol 38:200\u2013206. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2007.11.001","journal-title":"Pediatr Neurol"},{"key":"3862_CR77","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s00246-005-0909-4","volume":"26","author":"LW Markham","year":"2005","unstructured":"Markham LW, Spicer RL, Khoury PR et al (2005) Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatr Cardiol 26:768\u2013771. https:\/\/doi.org\/10.1007\/s00246-005-0909-4","journal-title":"Pediatr Cardiol"},{"key":"3862_CR78","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.nmd.2008.03.002","volume":"18","author":"LW Markham","year":"2008","unstructured":"Markham LW, Kinnett K, Wong BL et al (2008) Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord 18:365\u2013370. https:\/\/doi.org\/10.1016\/j.nmd.2008.03.002","journal-title":"Neuromuscul Disord"},{"key":"3862_CR79","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejpn.2008.02.006","volume":"13","author":"S Mavrogeni","year":"2009","unstructured":"Mavrogeni S, Papavasiliou A, Douskou M et al (2009) Effect of deflazacort on cardiac and sternocleidomastoid muscles in Duchenne muscular dystrophy: a magnetic resonance imaging study. Eur J Paediatr Neurol 13:34\u201340. https:\/\/doi.org\/10.1016\/j.ejpn.2008.02.006","journal-title":"Eur J Paediatr Neurol"},{"key":"3862_CR80","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jacc.2012.12.008","volume":"61","author":"G Schram","year":"2013","unstructured":"Schram G, Fournier A, Leduc H et al (2013) All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. J Am Coll Cardiol 61:948\u2013954. https:\/\/doi.org\/10.1016\/j.jacc.2012.12.008","journal-title":"J Am Coll Cardiol"},{"key":"3862_CR81","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/s0002-9149(02)03429-x","volume":"91","author":"CK Silversides","year":"2003","unstructured":"Silversides CK, Webb GD, Harris VA, Biggar DW (2003) Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol 91:769\u2013772. https:\/\/doi.org\/10.1016\/s0002-9149(02)03429-x","journal-title":"Am J Cardiol"},{"key":"3862_CR82","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jacc.2012.12.011","volume":"61","author":"GW Dec","year":"2013","unstructured":"Dec GW (2013) Steroid therapy effectively delays Duchenne\u2019s cardiomyopathy. J Am Coll Cardiol 61:955\u2013956. https:\/\/doi.org\/10.1016\/j.jacc.2012.12.011","journal-title":"J Am Coll Cardiol"},{"key":"3862_CR83","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ahj.2007.05.014","volume":"154","author":"D Duboc","year":"2007","unstructured":"Duboc D, Meune C, Pierre B et al (2007) Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years\u2019 follow-up. Am Heart J 154:596\u2013602. https:\/\/doi.org\/10.1016\/j.ahj.2007.05.014","journal-title":"Am Heart J"},{"key":"3862_CR84","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.jacc.2004.09.078","volume":"45","author":"D Duboc","year":"2005","unstructured":"Duboc D, Meune C, Lerebours G et al (2005) Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol 45:855\u2013857. https:\/\/doi.org\/10.1016\/j.jacc.2004.09.078","journal-title":"J Am Coll Cardiol"},{"key":"3862_CR85","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1253\/circj.70.991","volume":"70","author":"H Kajimoto","year":"2006","unstructured":"Kajimoto H, Ishigaki K, Okumura K et al (2006) Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy. Circ J 70:991\u2013994. https:\/\/doi.org\/10.1253\/circj.70.991","journal-title":"Circ J"},{"key":"3862_CR86","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41582-019-0203-3","volume":"15","author":"IEC Verhaart","year":"2019","unstructured":"Verhaart IEC, Aartsma-Rus A (2019) Therapeutic developments for Duchenne muscular dystrophy. Nat Rev Neurol 15:373\u2013386. https:\/\/doi.org\/10.1038\/s41582-019-0203-3","journal-title":"Nat Rev Neurol"},{"key":"3862_CR87","doi-asserted-by":"publisher","DOI":"10.1007\/s43440-020-00134-x","author":"A \u0141oboda","year":"2020","unstructured":"\u0141oboda A, Dulak J (2020) Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future. Pharmacol Rep. https:\/\/doi.org\/10.1007\/s43440-020-00134-x","journal-title":"Pharmacol Rep"},{"key":"3862_CR88","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3233\/JND-150116","volume":"2","author":"A Hotta","year":"2015","unstructured":"Hotta A (2015) Genome editing gene therapy for duchenne muscular dystrophy. J Neuromuscul Dis 2:343\u2013355. https:\/\/doi.org\/10.3233\/JND-150116","journal-title":"J Neuromuscul Dis"},{"key":"3862_CR89","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, Tanabe K, Ohnuki M et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861\u2013872. https:\/\/doi.org\/10.1016\/j.cell.2007.11.019","journal-title":"Cell"},{"key":"3862_CR90","doi-asserted-by":"publisher","first-page":"8597","DOI":"10.1038\/srep08597","volume":"5","author":"J Stepniewski","year":"2015","unstructured":"Stepniewski J, Kachamakova-Trojanowska N, Ogrocki D et al (2015) Induced pluripotent stem cells as a model for diabetes investigation. Sci Rep 5:8597. https:\/\/doi.org\/10.1038\/srep08597","journal-title":"Sci Rep"},{"key":"3862_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.00014","author":"P Beauchamp","year":"2020","unstructured":"Beauchamp P, Jackson CB, Ozhathil LC et al (2020) 3D Co-culture of hiPSC-derived cardiomyocytes with cardiac fibroblasts improves tissue-like features of cardiac spheroids. Front Mol Biosci. https:\/\/doi.org\/10.3389\/fmolb.2020.00014","journal-title":"Front Mol Biosci"},{"key":"3862_CR92","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3389\/fcvm.2019.00087","volume":"6","author":"C Zuppinger","year":"2019","unstructured":"Zuppinger C (2019) 3D cardiac cell culture: a critical review of current technologies and applications. Front Cardiovasc Med 6:87. https:\/\/doi.org\/10.3389\/fcvm.2019.00087","journal-title":"Front Cardiovasc Med"},{"key":"3862_CR93","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1242\/dmm.019505","volume":"8","author":"B Lin","year":"2015","unstructured":"Lin B, Li Y, Han L et al (2015) Modeling and study of the mechanism of dilated cardiomyopathy using induced pluripotent stem cells derived from individuals with Duchenne muscular dystrophy. Dis Model Mech 8:457\u2013466. https:\/\/doi.org\/10.1242\/dmm.019505","journal-title":"Dis Model Mech"},{"key":"3862_CR94","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1111\/jcmm.14124","volume":"23","author":"B Eisen","year":"2019","unstructured":"Eisen B, Ben Jehuda R, Cuttitta AJ et al (2019) Electrophysiological abnormalities in induced pluripotent stem cell-derived cardiomyocytes generated from Duchenne muscular dystrophy patients. J Cell Mol Med 23:2125\u20132135. https:\/\/doi.org\/10.1111\/jcmm.14124","journal-title":"J Cell Mol Med"},{"key":"3862_CR95","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.stem.2016.01.021","volume":"18","author":"CS Young","year":"2016","unstructured":"Young CS, Hicks MR, Ermolova NV et al (2016) A single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells. Cell Stem Cell 18:533\u2013540. https:\/\/doi.org\/10.1016\/j.stem.2016.01.021","journal-title":"Cell Stem Cell"},{"key":"3862_CR96","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41591-019-0738-2","volume":"26","author":"A Moretti","year":"2020","unstructured":"Moretti A, Fonteyne L, Giesert F et al (2020) Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy. Nat Med 26:207\u2013214. https:\/\/doi.org\/10.1038\/s41591-019-0738-2","journal-title":"Nat Med"},{"key":"3862_CR97","doi-asserted-by":"publisher","first-page":"149","DOI":"10.5966\/sctm.2013-0095","volume":"3","author":"R Abujarour","year":"2014","unstructured":"Abujarour R, Bennett M, Valamehr B et al (2014) Myogenic differentiation of muscular dystrophy-specific induced pluripotent stem cells for use in drug discovery. Stem Cells Transl Med 3:149\u2013160. https:\/\/doi.org\/10.5966\/sctm.2013-0095","journal-title":"Stem Cells Transl Med"},{"key":"3862_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/cells7120253","author":"L Danisovic","year":"2018","unstructured":"Danisovic L, Culenova M, Csobonyeiova M (2018) Induced pluripotent stem cells for duchenne muscular dystrophy modeling and therapy. Cells. https:\/\/doi.org\/10.3390\/cells7120253","journal-title":"Cells"},{"key":"3862_CR99","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1242\/dmm.018424","volume":"8","author":"JW McGreevy","year":"2015","unstructured":"McGreevy JW, Hakim CH, McIntosh MA, Duan D (2015) Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis Model Mech 8:195\u2013213. https:\/\/doi.org\/10.1242\/dmm.018424","journal-title":"Dis Model Mech"},{"key":"3862_CR100","first-page":"909","volume":"135","author":"JL Carpenter","year":"1989","unstructured":"Carpenter JL, Hoffman EP, Romanul FC et al (1989) Feline muscular dystrophy with dystrophin deficiency. Am J Pathol 135:909\u2013919","journal-title":"Am J Pathol"},{"key":"3862_CR101","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0022-510x(92)90022-d","volume":"110","author":"FP Gaschen","year":"1992","unstructured":"Gaschen FP, Hoffman EP, Gorospe JR et al (1992) Dystrophin deficiency causes lethal muscle hypertrophy in cats. J Neurol Sci 110:149\u2013159. https:\/\/doi.org\/10.1016\/0022-510x(92)90022-d","journal-title":"J Neurol Sci"},{"key":"3862_CR102","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00335-011-9382-y","volume":"23","author":"JN Kornegay","year":"2012","unstructured":"Kornegay JN, Bogan JR, Bogan DJ et al (2012) Canine models of duchenne muscular dystrophy and their use in therapeutic strategies. Mamm Genome 23:85\u2013108. https:\/\/doi.org\/10.1007\/s00335-011-9382-y","journal-title":"Mamm Genome"},{"key":"3862_CR103","doi-asserted-by":"publisher","first-page":"e012443","DOI":"10.1161\/JAHA.119.012443","volume":"8","author":"L-J Guo","year":"2019","unstructured":"Guo L-J, Soslow JH, Bettis AK et al (2019) Natural history of cardiomyopathy in adult dogs with golden retriever muscular dystrophy. J Am Heart Assoc 8:e012443. https:\/\/doi.org\/10.1161\/JAHA.119.012443","journal-title":"J Am Heart Assoc"},{"key":"3862_CR104","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1892\/0891-6640(1999)013<0346:ciddhf>2.3.co;2","volume":"13","author":"L Gaschen","year":"1999","unstructured":"Gaschen L, Lang J, Lin S et al (1999) Cardiomyopathy in dystrophin-deficient hypertrophic feline muscular dystrophy. J Vet Intern Med 13:346\u2013356. https:\/\/doi.org\/10.1892\/0891-6640(1999)013%3c0346:ciddhf%3e2.3.co;2","journal-title":"J Vet Intern Med"},{"key":"3862_CR105","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3233\/JND-150106","volume":"2","author":"J Hyzewicz","year":"2015","unstructured":"Hyzewicz J, Ruegg UT, Takeda S (2015) Comparison of experimental protocols of physical exercise for mdx mice and duchenne muscular dystrophy patients. J Neuromuscul Dis 2:325\u2013342. https:\/\/doi.org\/10.3233\/JND-150106","journal-title":"J Neuromuscul Dis"},{"key":"3862_CR106","doi-asserted-by":"publisher","first-page":"42ra54","DOI":"10.1126\/scitranslmed.3000692","volume":"2","author":"K Chandrasekharan","year":"2010","unstructured":"Chandrasekharan K, Yoon JH, Xu Y et al (2010) A human-specific deletion in mouse Cmah increases disease severity in the mdx model of Duchenne muscular dystrophy. Sci Transl Med 2:42ra54. https:\/\/doi.org\/10.1126\/scitranslmed.3000692","journal-title":"Sci Transl Med"},{"key":"3862_CR107","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.043562","author":"M van Putten","year":"2020","unstructured":"van Putten M, Lloyd EM, de Greef JC et al (2020) Mouse models for muscular dystrophies: an overview. Dis Model Mech. https:\/\/doi.org\/10.1242\/dmm.043562","journal-title":"Dis Model Mech"},{"key":"3862_CR108","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/hmg\/ddv460","volume":"25","author":"WD Coley","year":"2016","unstructured":"Coley WD, Bogdanik L, Vila MC et al (2016) Effect of genetic background on the dystrophic phenotype in mdx mice. Hum Mol Genet 25:130\u2013145. https:\/\/doi.org\/10.1093\/hmg\/ddv460","journal-title":"Hum Mol Genet"},{"key":"3862_CR109","doi-asserted-by":"publisher","first-page":"8110","DOI":"10.1096\/fj.201802488R","volume":"33","author":"M van Putten","year":"2019","unstructured":"van Putten M, Putker K, Overzier M et al (2019) Natural disease history of the D2-mdx mouse model for Duchenne muscular dystrophy. FASEB J 33:8110\u20138124. https:\/\/doi.org\/10.1096\/fj.201802488R","journal-title":"FASEB J"},{"key":"3862_CR110","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/hmg\/ddy346","volume":"28","author":"CA Betts","year":"2019","unstructured":"Betts CA, McClorey G, Healicon R et al (2019) Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment. Hum Mol Genet 28:396\u2013406. https:\/\/doi.org\/10.1093\/hmg\/ddy346","journal-title":"Hum Mol Genet"},{"key":"3862_CR111","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1089\/hum.2008.058","volume":"19","author":"B Bostick","year":"2008","unstructured":"Bostick B, Yue Y, Lai Y et al (2008) Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice. Hum Gene Ther 19:851\u2013856. https:\/\/doi.org\/10.1089\/hum.2008.058","journal-title":"Hum Gene Ther"},{"key":"3862_CR112","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.nmd.2004.04.007","volume":"14","author":"JG Quinlan","year":"2004","unstructured":"Quinlan JG, Hahn HS, Wong BL et al (2004) Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscul Disord 14:491\u2013496. https:\/\/doi.org\/10.1016\/j.nmd.2004.04.007","journal-title":"Neuromuscul Disord"},{"key":"3862_CR113","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.nmd.2011.07.003","volume":"22","author":"JL Chun","year":"2012","unstructured":"Chun JL, O\u2019Brien R, Berry SE (2012) Cardiac dysfunction and pathology in the dystrophin and utrophin-deficient mouse during development of dilated cardiomyopathy. Neuromuscul Disord 22:368\u2013379. https:\/\/doi.org\/10.1016\/j.nmd.2011.07.003","journal-title":"Neuromuscul Disord"},{"key":"3862_CR114","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1073\/pnas.96.1.220","volume":"96","author":"LA Megeney","year":"1999","unstructured":"Megeney LA, Kablar B, Perry RL et al (1999) Severe cardiomyopathy in mice lacking dystrophin and MyoD. Proc Natl Acad Sci USA 96:220\u2013225. https:\/\/doi.org\/10.1073\/pnas.96.1.220","journal-title":"Proc Natl Acad Sci USA"},{"key":"3862_CR115","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/cvr\/cvz236","volume":"116","author":"B Krist","year":"2020","unstructured":"Krist B, Podkalicka P, Mucha O et al (2020) miR-378a influences vascularization in skeletal muscles. Cardiovasc Res 116:1386\u20131397. https:\/\/doi.org\/10.1093\/cvr\/cvz236","journal-title":"Cardiovasc Res"},{"key":"3862_CR116","doi-asserted-by":"crossref","unstructured":"Krist B, Florczyk U, Pietraszek-Gremplewicz K et al (2015) The role of miR-378a in metabolism, angiogenesis, and muscle biology. Int J Endocrinol. https:\/\/www.hindawi.com\/journals\/ije\/2015\/281756\/. Accessed 5 Sep 2020","DOI":"10.1155\/2015\/281756"},{"key":"3862_CR117","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.135576","author":"P Podkalicka","year":"2020","unstructured":"Podkalicka P, Mucha O, Bronisz-Budzy\u0144ska I et al (2020) Lack of miR-378 attenuates muscular dystrophy in mdx mice. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.135576","journal-title":"JCI Insight"},{"key":"3862_CR118","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12968-016-0244-3","volume":"18","author":"S Becker","year":"2016","unstructured":"Becker S, Florian A, Patrascu A et al (2016) Identification of cardiomyopathy associated circulating miRNA biomarkers in patients with muscular dystrophy using a complementary cardiovascular magnetic resonance and plasma profiling approach. J Cardiovasc Magn Reson 18:25. https:\/\/doi.org\/10.1186\/s12968-016-0244-3","journal-title":"J Cardiovasc Magn Reson"},{"key":"3862_CR119","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.ajpath.2013.01.020","volume":"182","author":"C Hourd\u00e9","year":"2013","unstructured":"Hourd\u00e9 C, Joanne P, Medja F et al (2013) Voluntary physical activity protects from susceptibility to skeletal muscle contraction-induced injury but worsens heart function in mdx mice. Am J Pathol 182:1509\u20131518. https:\/\/doi.org\/10.1016\/j.ajpath.2013.01.020","journal-title":"Am J Pathol"},{"key":"3862_CR120","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/mus.21783","volume":"42","author":"JM Costas","year":"2010","unstructured":"Costas JM, Nye DJ, Henley JB, Plochocki JH (2010) Voluntary exercise induces structural remodeling in the hearts of dystrophin-deficient mice. Muscle Nerve 42:881\u2013885. https:\/\/doi.org\/10.1002\/mus.21783","journal-title":"Muscle Nerve"},{"key":"3862_CR121","doi-asserted-by":"publisher","first-page":"8986","DOI":"10.1038\/srep08986","volume":"5","author":"CA Betts","year":"2015","unstructured":"Betts CA, Saleh AF, Carr CA et al (2015) Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice. Sci Rep 5:8986. https:\/\/doi.org\/10.1038\/srep08986","journal-title":"Sci Rep"},{"key":"3862_CR122","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/s0014-5793(02)02739-4","volume":"520","author":"A Nakamura","year":"2002","unstructured":"Nakamura A, Yoshida K, Takeda S et al (2002) Progression of dystrophic features and activation of mitogen-activated protein kinases and calcineurin by physical exercise, in hearts of mdx mice. FEBS Lett 520:18\u201324. https:\/\/doi.org\/10.1016\/s0014-5793(02)02739-4","journal-title":"FEBS Lett"},{"key":"3862_CR123","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1161\/CIRCRESAHA.107.162982","volume":"102","author":"B Bostick","year":"2008","unstructured":"Bostick B, Yue Y, Long C, Duan D (2008) Prevention of dystrophin-deficient cardiomyopathy in twenty-one-month-old carrier mice by mosaic dystrophin expression or complementary dystrophin\/utrophin expression. Circ Res 102:121\u2013130. https:\/\/doi.org\/10.1161\/CIRCRESAHA.107.162982","journal-title":"Circ Res"},{"key":"3862_CR124","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.nmd.2011.10.025","volume":"22","author":"IEC Verhaart","year":"2012","unstructured":"Verhaart IEC, van Duijn RJM, den Adel B et al (2012) Assessment of cardiac function in three mouse dystrophinopathies by magnetic resonance imaging. Neuromuscul Disord 22:418\u2013426. https:\/\/doi.org\/10.1016\/j.nmd.2011.10.025","journal-title":"Neuromuscul Disord"},{"key":"3862_CR125","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1006\/jmcc.1999.1018","volume":"31","author":"BL Bia","year":"1999","unstructured":"Bia BL, Cassidy PJ, Young ME et al (1999) Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy. J Mol Cell Cardiol 31:1857\u20131862. https:\/\/doi.org\/10.1006\/jmcc.1999.1018","journal-title":"J Mol Cell Cardiol"},{"key":"3862_CR126","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1093\/hmg\/ddl018","volume":"15","author":"C Guo","year":"2006","unstructured":"Guo C, Willem M, Werner A et al (2006) Absence of alpha 7 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophy. Hum Mol Genet 15:989\u2013998. https:\/\/doi.org\/10.1093\/hmg\/ddl018","journal-title":"Hum Mol Genet"},{"key":"3862_CR127","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/ncb2790","volume":"15","author":"F Mourkioti","year":"2013","unstructured":"Mourkioti F, Kustan J, Kraft P et al (2013) Role of telomere dysfunction in cardiac failure in Duchenne muscular dystrophy. Nat Cell Biol 15:895\u2013904. https:\/\/doi.org\/10.1038\/ncb2790","journal-title":"Nat Cell Biol"},{"key":"3862_CR128","doi-asserted-by":"publisher","first-page":"e110371","DOI":"10.1371\/journal.pone.0110371","volume":"9","author":"T Larcher","year":"2014","unstructured":"Larcher T, Lafoux A, Tesson L et al (2014) Characterization of dystrophin deficient rats: a new model for Duchenne muscular dystrophy. PLoS ONE 9:e110371. https:\/\/doi.org\/10.1371\/journal.pone.0110371","journal-title":"PLoS ONE"},{"key":"3862_CR129","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.032201","author":"T Sui","year":"2018","unstructured":"Sui T, Lau YS, Liu D et al (2018) A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR\/Cas9. Dis Model Mech. https:\/\/doi.org\/10.1242\/dmm.032201","journal-title":"Dis Model Mech"},{"key":"3862_CR130","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/s0735-1097(10)80202-5","volume":"17","author":"NS Moise","year":"1991","unstructured":"Moise NS, Valentine BA, Brown CA et al (1991) Duchenne\u2019s cardiomyopathy in a canine model: electrocardiographic and echocardiographic studies. J Am Coll Cardiol 17:812\u2013820. https:\/\/doi.org\/10.1016\/s0735-1097(10)80202-5","journal-title":"J Am Coll Cardiol"},{"key":"3862_CR131","first-page":"671","volume":"135","author":"BA Valentine","year":"1989","unstructured":"Valentine BA, Cummings JF, Cooper BJ (1989) Development of Duchenne-type cardiomyopathy. Morphologic studies in a canine model. Am J Pathol 135:671\u2013678","journal-title":"Am J Pathol"},{"key":"3862_CR132","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/cvr\/cvs161","volume":"95","author":"JB Su","year":"2012","unstructured":"Su JB, Cazorla O, Blot S et al (2012) Bradykinin restores left ventricular function, sarcomeric protein phosphorylation, and e\/nNOS levels in dogs with Duchenne muscular dystrophy cardiomyopathy. Cardiovasc Res 95:86\u201396. https:\/\/doi.org\/10.1093\/cvr\/cvs161","journal-title":"Cardiovasc Res"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-021-03862-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-021-03862-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-021-03862-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T23:42:21Z","timestamp":1625528541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-021-03862-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,6]]},"references-count":132,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["3862"],"URL":"https:\/\/doi.org\/10.1007\/s00018-021-03862-2","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,6]]},"assertion":[{"value":"28 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}